Clinical trials: Dual Anti-Platelet Therapy
Stable Angina
COBRA SHIELD OCT Study
Phase one of this study is a prospective, randomized (2:1), pilot study that will evaluate COBRA PzF vascular healing patterns and thrombus formation with Optical Coherence Tomography (OCT) at 3 months after stent implantation in…
- Trial name
- NCT02224235
- Testing
- Aspirin, Resolute Integrity DES, COBRA PzF
- Where
- 2 sites in Finland
- Volunteers
- 8 people
- Sponsor
- CeloNova BioSciences, Inc.
Intracranial Arteriosclerosis, Intracranial Artery Stenosis
Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation
This study is a prospective, multicenter, open-label, randomized controlled clinical trial, aims to assess the clinical non-inferiority of 3 months (short-term) vs 6 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in…
- Conditions
- Intracranial Arteriosclerosis, Intracranial Artery Stenosis, Drug-Eluting Stents
- Trial name
- NCT06857045
- Testing
- NOVA intracranial sirolimus-eluting stent system
- Where
- China
- Sponsor
- Sino Medical Sciences Technology Inc.
Drug-Eluting Stents, Percutaneous Coronary Intervention
Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation
This study is a prospective,multi-center, open-label, randomized controlled clinical trial,aims to assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in…
- Trial name
- NCT03008083
- Testing
- 3 months DAPT, 12 months DAPT
- Where
- China
- Volunteers
- 2,446 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT
This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and Outside United States (OUS).
- Trial name
- NCT01925794
- Testing
- COBRA PzF
- Where
- 35 sites in United States, France and 5 more
- Volunteers
- 296 people
- Sponsor
- CeloNova BioSciences, Inc.
Stroke, Ischemic Attack, Transient
Platelet Reactivity in Acute Non-disabling Cerebrovascular Events
Ticagrelor is a reversible and direct-acting oral antagonist of the P2Y12 (Purinergic receptor P2Y, G-protein coupled, 12) receptor for adenosine diphosphate, which provides faster, greater, and more consistent P2Y12 inhibition…
- Trial name
- PRINCE (NCT02506140)
- Testing
- Ticagrelor and Acetylsalicylic acid, Clopidogrel and Acetylsalicylic acid
- Where
- 25 sites in China
- Volunteers
- 675 people
- Sponsor
- Beijing Tiantan Hospital
Coronary Artery Disease, Myocardial Ischemia
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
This study is a prospective, multicenter, parallel, open-label, randomized, controlled, superiority trial. It is planned to recruit 8,250 patients with multi-vessel disease(MVD), and the patients will be followed-up for at least…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases
- Trial name
- NCT04624854
- Testing
- Clopidogrel and aspirin dual-antiplatelet therapy, Aspirin monotherapy
- Where
- 97 sites in China
- Volunteers
- 8,250 people
- Sponsor
- Harbin Medical University
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Transient Ischemic Attacks, Minor Stroke
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
The primary goal of the research is to determine if 10 days of dual anti-platelet treatment is as effective as 30 days of similar treatment in the prevention of stroke, myocardial ischemia (MI) and death in patients with TIAs and…
- Trial name
- MENA-TIA (NCT02144831)
- Testing
- anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
- Where
- Canada
- Sponsor
- University of Alberta
Coronary Artery Disease
CYPRESS - CYPHER for Evaluating Sustained Safety
CYPRESS: A Prospective,Randomized,Multi-Center,Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with…
- Trial name
- NCT00954707
- Testing
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Where
- United States
- Volunteers
- 2,509 people
- Sponsor
- Cordis US Corp.
Coronary Heart Disease
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen
Objectives 1. To compare the safety and long-term effectiveness of coronary stenting with the new platform Everolimus-Eluting coronary stenting system (EECSS, Promus Element) compared with the Zotarolimus-Eluting coronary…
- Trial name
- HOST-ASSURE (NCT01267734)
- Testing
- Everolimus-eluting coronary stenting system (EECSS, Promus Element), Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute), Triple anti-platelet therapy (TAT)
- Where
- South Korea
- Volunteers
- 3,750 people
- Sponsor
- Seoul National University Hospital
Medication Non-adherence, Stent Thrombosis
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients
The purpose of this observational research study is to determine when and why patients discontinue, interrupt, or disrupt the regimen of anti-platelet medications prescribed following stent implantation, and to examine the…
- Trial name
- PARIS (NCT00998127)
- Where
- 15 sites in United States, France and 3 more
- Volunteers
- 5,031 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.
- Conditions
- Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy, Aged, Percutaneous Coronary Intervention
- Trial name
- NCT04999293
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 1,505 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Cardiovascular Diseases, Interventional Cardiology
Repetitive Assessement of PRECISE-DAPT Score
Patients treated with percutaneous coronary intervention (PCI) require dual antiplatelet therapy (DAPT). Preliminary assessment of the PRECISE-DAPT score is mandatory in order to assess the risk of bleeding while on DAPT.
- Trial name
- RE-SCORE (NCT03848572)
- Testing
- Repetitive assessment of PRECISE-DAPT score
- Where
- 2 sites in Italy
- Volunteers
- 500 people
- Sponsor
- University of Roma La Sapienza
Anti-platelet Therapy
Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy and Mean Precise-DAPT and DAPT Scores in Turkey
Coronary Artery Disease (CAD) is leading cause of death worldwide. Most of them underwent coronary angiography and they have to use dual anti-platelet therapy.
- Trial name
- NCT03601013
- Testing
- Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 963 people
- Sponsor
- Cardiovascular Academy Society, Turkey
Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI)
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
The study aims to determine the feasibility and clinical utility of incorporating precision medicine approaches, incorporating both cytochrome P450 2C19 (CYP2C19) genotyping and platelet reactivity phenotyping, with standard of…
- Conditions
- Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI, Unstable Angina (UA)
- Trial name
- NCT04090281
- Testing
- CYP2C19 genotyping
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Southern California
Acute Coronary Syndrome
Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation
Investigating Synergistic Effects of Apixaban with Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation
- Trial name
- SEARCH (NCT03746782)
- Testing
- Flow Cytrometry; Thrombin Generation Assay
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CirQuest Labs, LLC
Non-ST Segment Elevation Myocardial Infarction
Anfibatide Phase Ib-IIa Clinical Trial
Investigate the safety and efficacy of Anfibatide in non-ST segment myocardial infarction patients
- Trial name
- NCT01585259
- Testing
- Anfibatide
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Lee's Pharmaceutical Limited
Coronary Artery Disease, DES
A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial
We hypothesized that clopidogrel mono-therapy will not be inferior to the extended DAPT in terms of the occurrence of both ischemic and bleeding events, for lesions or patients at high risk for either ischemic or bleeding…
- Trial name
- NCT03947229
- Testing
- Clopidogrel mono-therapy, Dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,200 people
- Sponsor
- Yonsei University
Coronary Artery Disease, Atherosclerosis
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy
The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Stent Placement
- Trial name
- SYNIVUS-DAPT (NCT03606642)
- Testing
- Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- HonorHealth Research Institute
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Dual Anti-platelet Therapy
Aspirin-Free Strategy After 3-6 Month Dual Antiplatelet Therapy in Acute Coronary Syndrome
This randomized controlled trial aims to evaluate the safety and efficacy of an aspirin-free strategy after 3-6 months of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) who have undergone complete…
- Trial name
- NCT07736196
- Testing
- Aspirin-Free Strategy, Dual Antiplatelet Therapy
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Assiut University